title: Clinical and biological distinctions between type I and type II acquired angioedema.
authors.forename: Laurence
authors.initials: L
authors.lastname: Bouillet-Claveyrolas
authors.forename: Denise
authors.initials: D
authors.lastname: Ponard
authors.forename: Christian
authors.initials: C
authors.lastname: Drouet
authors.forename: Christian
authors.initials: C
authors.lastname: Massot
mesh_terms: D000799:Angioedema / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001323:Autoantibodies; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000276:immunology; D003613:Danazol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D014148:Tranexamic Acid / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001323:Autoantibodies; D003174:Complement C1 Inactivator Proteins; D014148:Tranexamic Acid; D003613:Danazol